Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Troublesome volume...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Apr 06, 2021 12:00pm
173 Views
Post# 32941794

RE:Troublesome volume...

RE:Troublesome volume...
Harper75 wrote: I'm not certain we are seeing dividends from the STERN promotional contract....


Not sure exactly why ATE is using Stern.  Could be pure networking and developing contacts for all we know.  I think they pay them monthly so when they have what they need, can notify them of cancellation.  ATE will have to decide when they've had enough.

Also, I just noticed another acquisition ... Amgen is buying 5 Prime for $1.9B.  They completed P2 and are getting ready for P3 in solid stomach tumors (with additional possible indications).  Looks like the global stomach tumor market is worth $8B - different margin on sales (I'm sure) but with a higher risk profile compared to ATE.  Regardless ... just saying the appetite for acquisitions is real and many Big Pharma's need acquisitions in order to grow future revenues.

https://www.fool.com/investing/2021/03/25/is-amgens-acquisition-of-five-prime-a-good-move-fo/

https://www.fool.com/investing/2021/03/25/is-amgens-acquisition-of-five-prime-a-good-move-fo/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities